Optimer to file fidaxomicin after second positive Phase III study
This article was originally published in Scrip
Executive Summary
Optimer Pharmaceuticals' narrow-spectrum antibiotic fidaxomicin has met the non-inferiority primary endpoint of its second Phase III study for the treatment of Clostridium difficile infections.